After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Immunovant Inc is $2.93B. A total of 1.74 million shares were traded on the day, compared to an average of 1.36M shares.
In the most recent transaction, Stout Jay S sold 2,805 shares of IMVT for 18.15 per share on Jul 23 ’25. After the transaction, the Chief Technology Officer now owns 204,919 company shares. In a previous transaction on Jul 23 ’25, Geffner Michael sold 2,385 shares at 18.15 per share. IMVT shares that Chief Medical Officer owns now total 221,825.
Among the insiders who sold shares, Geffner Michael disposed of 1,160 shares on Jul 09 ’25 at a per-share price of $17.24. This resulted in the Chief Medical Officer holding 224,210 shares of IMVT after the transaction. In another insider transaction, Stout Jay S sold 1,519 shares at $17.24 per share on Jul 09 ’25. Company shares held by the Chief Technology Officer now total 207,724.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, IMVT has a high of $32.10 and a low of $12.72.
As of this writing, IMVT has an earnings estimate of -$0.72 per share for the current quarter. EPS was calculated based on a consensus of 12.0 estimates, with a high estimate of -$0.59 per share and a lower estimate of -$0.8. The company reported an EPS of -$0.74 in the last quarter
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. IMVT’s latest balance sheet shows that the firm has $493.82M in Cash & Short Term Investments as of fiscal 2022. There were $2.36M in debt and $44.52M in liabilities at the time. Its Book Value Per Share was $3.56, while its Total Shareholder’s Equity was $469.82M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IMVT is Buy with a score of 4.41.
